Pfizer Halts Development of Sisunatovir, an RSV Antiviral, After Phase II/III Trials
U.S. pharmaceutical giant Pfizer (NYSE: PFE) has decided to discontinue the development of sisunatovir, an...
OTCMKTS: LIANY
Blue Shield Biotech Faces Bankruptcy Proceedings After Missing Debt Payments
The Nanjing Qixia District People’s Court has accepted a bankruptcy liquidation case for Blue Shield...
LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend
LianBio (OTCMKTS: LIANY), one of China’s prominent biotechnology firms, has announced plans to wind down...
LianBio Board Turns Down Concentra Biosciences Buyout Offer
China-based LianBio (OTCMKTS: LIANY) has announced that its board of directors has unanimously decided not...
Concentra Biosciences Targets China-Based Biotech LianBio in Unsolicited Takeover Bid
LianBio (OTCMKTS: LIANY), a China-based biotech firm, has become the target of an unsolicited takeover...
LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial
Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement...
LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General...
LianBio’s TP-03 Begins Phase III Trial for Demodectic Blepharitis in China
Shanghai-based biopharmaceutical company LianBio (OTCMKTS: LIANY) has announced the first patient dosing in a Phase...
LianBio Cancels Phase III Trial for Truseltiq in China Amid Global Halt
China-based LianBio (OTCMKTS: LIANY) revealed in an SEC filing that it is canceling work on...
LianBio Completes Enrollment for Mavacamten Phase III Trial in oHCM
China-based biotech LianBio (OTCMKTS: LIANY) announced that enrollment has been completed in the Phase III...